



Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

Mona O. Mohsen^{1,2,3*}, Monique Vogel², Carsten Riether⁴, Julius Muller¹, Silvia Salatino⁵, Nicola Ternette¹, Ariane C. Gomes¹, Gustavo Cabral-Miranda², Aadil El-Turabi¹, Christiane Ruedl⁶, Thomas M. Kundig⁷, Said Dermime³, Alexander Knuth³, Daniel E. Speiser⁸ and Martin F. Bachmann^{1,2}

¹ Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, United Kingdom, ² Department of BioMedical Research, Immunology RIA, University Hospital of Bern, Bern, Switzerland, ³ National Center for Cancer Care & Research, Doha, Qatar, ⁴ Department of Medical Oncology, University Hospital of Bern, Bern, Switzerland, ⁵ Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, ⁶ Division of Molecular Genetics and Cell Biology, Nanyang Technological University, Singapore, Singapore, ⁷ Department of Dermatology, University of Zurich, Zurich, Switzerland, ⁸ Department of Oncology, University of Lausanne, Lausanne, Switzerland

OPEN ACCESS

Edited by:

Brian J. Czerniecki,
Moffitt Cancer Center, United States

Reviewed by:

Catherine J. Wu,
Dana-Farber Cancer Institute,
United States
William Gillanders,
Washington University in St. Louis,
United States

*Correspondence:

Mona O. Mohsen
mona.mohsen@dbmr.unibe.ch;
monamona20@icloud.com

Specialty section:

This article was submitted to
Cancer Immunity and Immunotherapy,
a section of the journal
Frontiers in Immunology

Received: 10 January 2019

Accepted: 23 April 2019

Published: 15 May 2019

Citation:

Mohsen MO, Vogel M, Riether C,
Muller J, Salatino S, Ternette N,
Gomes AC, Cabral-Miranda G,
El-Turabi A, Ruedl C, Kundig TM,
Dermime S, Knuth A, Speiser DE and
Bachmann MF (2019) Targeting
Mutated Plus Germline Epitopes
Confers Pre-clinical Efficacy of an
Instantly Formulated Cancer
Nano-Vaccine.
Front. Immunol. 10:1015.
doi: 10.3389/fimmu.2019.01015

Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are sufficient, and whether the addition of germline antigens would enhance the therapeutic efficacy. We developed and used a personalized cancer nano-vaccine platform based on virus-like particles loaded with toll-like receptor ligands. We generated three sets of multi-target vaccines (MTV) to immunize against the aggressive B16F10 murine melanoma: one set based on germline epitopes (GL-MTV) identified by immunopeptidomics, another set based on mutated epitopes (Mutated-MTV) predicted by whole exome sequencing and a last set combines both germline and mutated epitopes (Mix-MTV). Our results demonstrate that both germline and mutated epitopes induced protection but the best therapeutic effect was achieved with the combination of both. Our platform is based on Cu-free click chemistry used for peptide-VLP coupling, thus enabling bedside production of a personalized cancer vaccine, ready for clinical translation.

Keywords: virus-like particles, vaccine, personalized, melanoma, neoantigen, mutated, germline

INTRODUCTION

Melanoma is the most aggressive type of skin cancer mostly due to its high metastatic potentials (1). The complexity of melanoma phenotype affects its responsiveness to various therapies. Therefore, scientists emphasize the need for personalized treatments, including vaccinations that target neoantigens representing the uniqueness of each patient's tumor (2, 3). Neoantigens are considered attractive because T-cells specific for these altered-self antigens are not expected to be attenuated by immune tolerance mechanisms as compared to T-cells specific for conserved self-antigens (4–6). Given the facts that powerful tumor infiltrating T-cells recognize multiple tumor antigens (7),

and that targeting of a single antigen allows tumors to relapse (8), it is desirable to target multiple antigens (3, 9, 10). However, identifying sufficient numbers of neoantigens may be difficult for many human tumors that often show low mutational burden such as prostate and pancreatic cancers (11–13). Targeting neoantigens by using synthetic long peptides (14), RNA-based vaccines (15), or DC-based vaccines (16) have so far only been done in patients with tumors of high mutational burden, essentially melanoma.

We have shown previously that VLPs derived from the bacteriophage Q β loaded with A-type CpGs and coupled to MelanA/MART-1 peptide can be efficiently processed by murine and human DCs for MHC-I presentation and induced strong CD8⁺ T-cell responses in HLA-A2 transgenic mice as well as in melanoma patients (17, 18). Recent research has also shown that CMP-001, a product that is also based on Q β -VLPs loaded with the same A-type CpGs induced tumor regressions in advanced melanoma patients treated by direct intra-tumoral injection, even though the VLPs used were not linked to tumor-specific antigens. Three clinical trials for CMP-001 are currently ongoing (NCT02680184, NCT03084640, and NCT03618641).

In this study, we have utilized VLPs to build up a personalized multi-target vaccine based on identified germline and predicted mutated peptides coupled to TLR 9-ligand loaded VLPs by the non-toxic bio-orthogonal Cu-free click chemistry. The generated vaccine candidates induced effective CD8⁺ T-cell responses and the strategy can also be implemented for solid tumors with low mutational burdens as identification of germline epitopes with high affinity to MHC-I molecules is always feasible.

MATERIALS AND METHODS

Production and Purification of Q β -VLPs

Q β -VLPs expression and production was performed as previously described in detail in Kozlovskaya et al. (19), Cielens et al. (20), and Storni et al. (21).

Packaging Q β -VLPs With B-Type CpGs

B-type CpGs (5'-TCC ATG ACG TTC CTG ATG CT-3') with phosphorothioate backbone was custom made by (IBA). Twenty mM HEPES (Sigma Aldrich) was used to solubilize Q β -VLPs and RNase A (Merck) was used to digest the naturally packaged RNA inside Q β -VLPs (1.2 mg/ml RNaseA/ 3 mg/ml Q β -VLPs) for 3 h at 37°C. The digestion was confirmed using 1% agarose gel and SYBR safe dye. Q β -VLPs was then repackaged with B-type CpGs (1.125 μ g/ 20 μ g Q β -VLPs) and packaging was also confirmed by using 1% agarose gel stained by SYBRsafe stain, while Q β -VLPs protein was detected by subsequent staining with coomassie blue.

Generation of Q β (CpGs)-p33 Vaccine Using SMPH Chemistry

B-type CpGs were packaged in Q β -VLPs as described earlier and then derivatized for 1 h at RT using SMPH (Succinimidyl 6-((beta-maleimidopropionamido)hexanoate)) (Thermo Fisher Scientific). Excess SMPH cross-linker was removed using Amicon centrifuge tubes of 100 kDa MWCO (Sigma-Aldrich). Modified p33 peptide—derived from Lymphocytic

Choriomeningitis Virus LCMV—was synthesized by the addition of GGC amino acids (a.a.) at the C-terminus “H-KAVYNFATMGGC-NH₂” (Pepscan BRESTO) to facilitate its coupling to SMPH cross-linker. The modified peptide was reconstituted in DMSO and added in 10-fold molar excess over Q β (CpGs)-VLPs monomer. The mixture was incubated for 1 h at RT and excess peptide was removed using Amicon centrifuge tubes. The coupling efficiency was tested by SDS-PAGE stained with coomassie blue and assessed by densitometric analysis of the SDS-PAGE by comparing Q β -VLP monomer bands to Q β -VLP monomer plus p33 after coupling.

Generation of Q β (CpGs)-p33 Vaccine and Multi-Target Vaccines Using DBCO (Cu-Free Click Chemistry)

B-type CpGs were packaged in Q β -VLPs as described earlier and then derivatized for 30 min at RT using DBCO (dibenzocyclooctyne NHS ester) (Sigma-Aldrich). Excess DBCO cross-linker was removed using Amicon centrifuge tubes of 100 kDa MWCO (Sigma-Aldrich). Modified p33 peptide was synthesized by the addition of GGCK a.a. and an azide (N₃) group at the C-terminus “H-KAVYNFATMGGCK(N₃)-NH₂” (Pepscan BRESTO) to facilitate its coupling to DBCO cross-linker. The peptides for the multi-target vaccines (MTV) were synthesized by the addition of extra 4 a.a. using their flanking protein sequence and an azide (N₃) group at the C-terminus. The generation of multi-target vaccine was done for each peptide separately. The modified peptides were reconstituted in DMSO and added in 10-fold molar excess over Q β (CpGs)-VLPs monomer. The vaccine was incubated for 30 min at RT and excess peptide was removed using Amicon centrifuge tubes. The efficiency of the coupling was tested as explained in section Generation of Q β (CpGs)-p33 vaccine using SMPH chemistry.

Mice

Wild type C57BL/6 mice were purchased from Harlan. Rag2^{-/-} mice on a C57BL/6 background were provided by Ochsenbein lab and bred in our pathogen-free animal facility. All *in vivo* experiments used 8–12-week-old female. All animal procedures were performed in accordance with the Swiss Animals Act (455.109.1) (September 2008, 5th) of University of Bern.

Measuring p33 Specific T-Cell Response With Tetramers

P33 (H-KAVYNFATM-NH₂) tetramers designed with H2-D^b allele and APC or PE fluorochrome (TCMetrix) was used to measure p33 specific T-cells. WT C57BL/6 mice (8–12 weeks old; Harlan) were vaccinated s.c. once with 50 μ g Q β (CpGs)-p33 vaccine coupled with SMPH or DBCO cross-linkers. Seven days later spleens were collected and smashed using 70 μ M cell strainer (Sigma-Aldrich). Cells were washed 1x with sterile PBS and RBCs were lysed using ACK lysis buffer. $\sim 1 \times 10^6$ cells were collected in 96-well V-bottom plate and stained with p33 tetramers (TCMetrix) followed by anti-CD8 α (53–6.7, BD Biosciences) for flow cytometric analysis by FACSCanto and FlowJo Software.

Intra-cellular Cytokine Staining for IFN- γ

Intra-cellular cytokine staining was performed on spleens or TILs of vaccinated mice to measure IFN- γ . $\sim 2 \times 10^6$ cells were collected from spleen or TIL and pulsed with 1 μ g of p33 peptide or with the mixture of germline peptides or mutated peptides or both according to the vaccine group for 6 h at 37°C with 1:1,000 Brefeldin A and Monensin (BD Biosciences). Cells were collected and washed 3x with sterile PBS/0.1% BSA. $\sim 1 \times 10^6$ cells were collected in 96-well V-bottom plate and stained with anti-CD8 α (53–6.7, BD Biosciences). Cells were then fixed with 100 μ l of the fixation buffer (Thermo Fisher Scientific) and permeabilized with 1x of the permeabilization buffer (Thermo Fisher Scientific). Cells were stained with anti-IFN- γ (XMG1.2, BD Biosciences) for flow cytometric analysis by FACSCanto and FlowJo Software.

CFSE *in vivo* Cytotoxic Assay

WT C57BL/6 mice (8–12 weeks old; Harlan) were vaccinated with a single s.c. injection of 50 μ g Q β (CpGs)-p33 vaccine coupled with SMPH cross-linker or DBCO cross-linker. Seven days later, target splenocytes from naïve WT C57BL/6 mice were collected and RBCs were lysed and divided into 2 groups. The 1st naïve splenocyte group was labeled with 2 μ M CFSE (Thermo Fisher Scientific) and kept un-pulsed while the 2nd naïve splenocytes group was first pulsed with 1 μ g p33 and then labeled with 10 μ M CFSE. The prepared target groups were mixed in 1:1 ratio and each previously vaccinated mouse received 1×10^7 of un-pulsed CFSE^{Low} cells and 1×10^7 of pulsed CFSE^{Hi} cells intravenously. Four hours later the spleens of the vaccinated mice were collected and analyzed by flow cytometry for frequency of CFSE^{Low} and CFSE^{Hi}. Specific lysis for each group was measured using the formula “Ratio = 100X(1–CFSE^{Hi} pulsed/CFSE^{Low} un-pulsed).”

Immunopeptidomics

B16F10 melanoma cell line transfected with p33 peptide was provided by Ochsenbein's lab and cultured in T-150 cm² flask using Dulbecco's modified Eagle's medium (DMEM) with 10% FBS and 1% Streptomycin/Penicillin. Cells at 80% confluency were washed 2x with sterile PBS and collected with scrapers, centrifuged and frozen at –80°C. Cells were lysed using 5 ml lysis buffer (1% Igepal, 300 mM sodium chloride, 100 mM Tris, pH 8.0) supplemented with protease inhibitor cocktail (Roche) for 30 min on ice. Lysates were cleared by two centrifugation steps at 500 g for 10 min and then 20,000 g for 60 min. One mg of anti-mouse MHC class I antibody (ATCC HB-51) was bound and cross-linked to 1 ml Protein G beads (GE healthcare). Lysates were incubated with the antibody beads over night at 4°C and washed subsequently with 50 mM Tris, pH 8.0 containing either 150, 450 mM, and no salt. Peptides were eluted with 5 ml 10% acetic acid and concentrated in a vacuum concentrator (Eppendorf). Peptides were then injected onto a 4.6 \times 50 mm ProSwift RP-1S column on an Ultimate 3000 system (Thermo Fisher Scientific). Peptides were separated from larger complex components by elution using a 500 μ l/min flow rate over 10 min from 2 to 30% ACN in 0.1% TFA. Alternate fractions that did not contain the beta-2-microglobulin were pooled and two final fractions were analyzed by nano-ultra performance

liquid chromatography tandem mass spectrometry (nUPLC-MS²) on a Fusion Lumos (Thermo Fisher Scientific). Peptides were separated on a Ultimate 3000 RSLCnano system (Thermo Fisher Scientific) using a PepMap C18 column, 2 μ m particle size, 75 μ m \times 50 cm (Thermo Fisher Scientific) with a 1 h linear gradient of 3–25% buffer B (0.1% formic acid, 5% DMSO in acetonitrile) in buffer A (0.1% formic acid, 5% DMSO in water) at a flow rate of 250 μ l/min. Peptides were introduced using an Easy-Spray source at 2000 V to a Fusion Lumos (Thermo Fisher Scientific) at 305°C. Full MS spectra were recorded from 300 to 1,500 m/z in the Orbitrap at 120,000 resolution with an AGC target of 400,000. Precursor selection was performed using TopSpeed mode at a cycle time of 2 s. Peptide ions were isolated using an isolation width of 1.2 amu and trapped at a maximal injection time of 120 ms with an AGC target of 300,000. Higher-energy collisional dissociation (HCD) fragmentation was induced at an energy setting of 28 for peptides with a charge state of 2–4, while singly charged peptides were fragmented at an energy setting of 32 at lower priority. Fragments were analyzed in the Orbitrap at 30,000 resolution. Analysis of raw data was performed using Peaks 7.5 software (Bioinformatics Solutions). Sequence interpretation of MS² spectra was carried out using databases containing all mus musculus UniProt database entries at a FDR of 1.4. Motif analysis of common a.a. in peptide sequences was performed using WebLogo 3.5 (weblogo.threeplusone.com). Peptide binding predictions were performed using NetMHCpan 4.0.

Whole Exome Sequencing

B16F10 melanoma cell line was cultured and collected as described earlier. DNA was isolated using Purelink genomic DNA mini kit according to manufacturer's instructions (Thermo Fisher Scientific), and gave a yield of 394 ng/ μ l. The quality of the DNA yield was assessed by loading an aliquot on 2% agarose gel. A library was prepared using Agilent SureSelect XT, based on the cRNA-baits targeted capture. The Mouse All Exon kit captures 49.6 Mb region that covers 221,784 exons within 24,306 genes. Sequencing was performed using HiSeq 2,500 machine with paired end 2x 25 run, aiming \times 100 (raw data) exome coverage by FASTERIS.

Bioinformatics Analysis of Whole Exome Sequencing

Sequenced reads from the B16F10 melanoma cell line sample were mapped to the Mus musculus reference genome assembly GRCm38 from NCBI using the software BWA-MEM (22) with default parameters. Supplementary alignments were removed and the resulting BAM file was sorted with SAMtools (23). Mapped reads were subsequently used as input for the variant calling software Platypus (version 0.8.1, specifying the option “–minFlank=0”) (24) to identify SNPs and short indels (<50 bp). The 74138 identified variants were annotated with standard R packages using GENCODE and further investigated with the Variant Effect Predictor Ensembl frame-work (VEP, release 90) (25). Peptides were extracted using a sliding window from +/–8AA to +/–14AA around the mutation. HLA




FIGURE 1 | Algorithm for the generation of a personalized melanoma vaccine platform based on VLPs. First, tumor-specific epitopes need to be identified in a systematic way. Here, immunopeptidomics approach has been used to identify potential tumor-specific germline epitopes and whole exome sequencing to predict the mutated ones. In a second step, the identified and predicted epitopes should be prioritized and this was basically achieved by bioinformatics and stimulation of tumor-infiltrating cells using *in vitro* T-cell assay. Next, the selected epitopes are extended to ~13–14 amino acids long peptides using their flanking protein sequence for the goal of targeting CD8⁺ CTL. The extended peptides are then synthesized and coupled to CpG-loaded VLPs using Cu-free click chemistry. A mix-multi target VLP-based vaccine is proposed.

Bio-orthogonal Cu-Free Click Chemistry; an Efficient Method for Coupling Antigens to VLPs to Enhance Their Immunogenicity


For the development of VLP-based vaccines, we previously used SMPH cross-linker to couple the peptide of interest to VLPs (21, 26–28). Linking of cysteine on peptides to lysine on VLPs by SMPH has indeed proven reliable for development of VLP-based vaccines. However, for the generation of a personalized cancer vaccine, the method may have several disadvantages, namely that epitope internal cysteine will also react with SMPH

on VLPs, causing their inactivation and non-reacted SMPH on VLPs is potentially toxic, requiring complex inactivation, and purification procedures after coupling. Therefore, this technique is not well-suited for rapid personalized vaccine production. For these reasons, we established a coupling method based on bio-orthogonal Cu-free click chemistry using a DBCO cross-linker (**Figure 2A**). This method is non-toxic and thus enables rapid and efficient coupling of regulatory compliant GMP produced VLPs and peptides that can potentially be done at patients' bedside. We compared the efficiency of DBCO based Cu-free click chemistry to the standard SMPH-based method by coupling p33 peptide as a model antigen- derived from LCMV to Q β -VLPs loaded with B-type CpGs. Cu-free click chemistry significantly enhanced the coupling of the model antigen to Q β -VLPs compared to SMPH when assessed by SDS-PAGE (**Figure 2B**) and densitometric analysis demonstrated enhanced peptide coupling by DBCO compared to SMPH (**Figure 2C**). In a next step, we compared the immunogenicity of the vaccines generated by the two coupling methods *in vivo*. WT C57BL/6 mice were vaccinated once subcutaneously (s.c.) with Q β (CpGs)-p33 vaccine prepared with SMPH or Cu-free click chemistry method. Q β -VLPs were packaged with B-type CpGs for successful activation of DCs and cross-priming. Seven days later, spleens were collected and tested for p33 specific CD8⁺ T-cells by assessing the percentage of p33 tetramer binding and IFN- γ production. Immunization of C57BL/6 mice with the Q β (CpGs)-p33 vaccine based on Cu-free click chemistry resulted in significant increase in p33 specific CD8⁺ T-cells ($p = 0.0012$) (**Figures 2D,G**) as well as significant production of IFN- γ ($p = 0.0421$) (**Figure 2E**) when compared to SMPH method. Lytic activity was also enhanced when assayed *in vivo* by performing CFSE cytotoxicity assay (**Figures 2F,H**). Thus, Cu-free click chemistry improves vaccine immunogenicity compared to the standard SMPH chemistry.

Identification and Prediction of CD8⁺ T-Cell Epitopes of B16F10 Melanoma Cells by Immunopeptidomics and Whole Exome Sequencing

In a next step, we performed immunopeptidomics for B16F10 murine melanoma cell line to identify peptides naturally presented on MHC-I molecules. As expected, a large number of MHC-I-associated peptides was identified (**Figures 3A,B**). Next, the peptides were evaluated for a number of essential physical parameters including the length, MHC haplotype (H2-D^b and/or H2-K^b) and affinity to MHC-I (high affinity ranking peptides) as summarized in **Table 2**. Using literature-based assessment of key characteristics such as being melanocyte-specific or a candidate oncogene were also considered. Six peptides were selected from immunopeptidomics for the generation of GL-MTV includes PMEL17, MTC-1, Calpastatin, ZFP518, TRP-2, and Caveoline2.

As for mutated peptides, Castle et al. have previously exploited the mutanome of B16F10 melanoma cell line and identified several non-synonymous point mutations



and tested >50 peptides *in vitro* (8). The most promising peptides with mutations in Kif18b and Cpsf3l genes were tested separately *in vivo* for their anti-tumor effect. They used long synthetic peptides (27 a.a.) targeting both CD8⁺ and CD4⁺ cells. Based on these findings we have carried out whole exome sequencing to confirm somatic point mutations in these two specific genes in our B16F10 cell line. We identified several non-synonymous single nucleotide variants (SNVs), including a point-mutation in the 13th exon of the Kif18b gene affecting the transcript ENSMUST00000021311 (Chr11:102,908,157; c.2367T>G; p.Lys739Asn) (Figure 3C), and in the 9th exon of the Cpsf3l gene affecting both ENSMUST00000120794 (Chr4:155,886,970; c.1021G>A; p.Asp292Asn) and ENSMUST00000030901 (Chr4:155,886,970; c.1087G>A; p.Asp314Asn) isoforms (Figure 3D). Accordingly, mutated Kif18b and Cpsf3l peptides were selected for the

generation of (Mutated-MTV). We have predicted the affinity of the selected two mutated peptides to H2-D^b and H2-K^b alleles *in silico* as summarized in Table 3. Please note that we have only selected the best two mutated peptides from B16F10 melanoma model as the mutation burden in most of other cancers is low and therefore it is not always feasible to predict mutated peptides.

In vitro Validation of Germline and Mutated Epitopes Identified by Immunopeptidomics and Predicted by Whole Exome Sequencing

Tumor-infiltrating lymphocytes are highly enriched with tumor specific T-cells and thus are the most relevant T-cell population in this regard (29). Therefore, we have used TILs to validate




TABLE 2 | The selected peptides from immunopeptidomics for the generation of germline-MTV.

Peptide	Sequence	# of a.a.	MHC haplotype	MHC-I affinity
Melanocyte protein PMEL (Melanocyte protein Pmel 17) (Premelanosome protein) (Silver locus protein) [Cleaved into: M-alpha; M-beta]	VLRYGSF	8	H2-K ^b	0.08
MTC-1 Malignant T- cell-amplified sequence 1 (MCT-1) (Multiple copies T-cell malignancies 1)	IGIENIHYL	9	H2-D ^b	0.01
Calpastatin (Calpain inhibitor)	SSPANISL	9	H2-D ^b , H2-K ^b	0.01
Zinc finger protein 518B	SSVQNKEYL	9	H2-K ^b	0.01
L-dopachrome tautomerase (DCT) (DT) (EC 5.3.3.12) (L-dopachrome Delta-isomerase) (SLATY locus protein) (Tyrosinase-related protein 2) (TRP-2) (TRP2)	SQVMNLHNL	9	H2-K ^b	0.015
Caveolin2	VMYKFLTIV	8	H2-D ^b , H2-K ^b	0.015

the natural immunogenicity of the six selected peptides from immunopeptidomics and the two mutated epitopes predicted by whole exome sequencing. The selected peptides were synthesized for this experiment as 8 or 9 a.a. to study their recognition by TILs. To this end, TILs were isolated from WT C57BL/6 bearing B16F10 melanoma tumors and cultivated *ex vivo* with IL-2 for 2–3 days. The used melanoma cell line has also

been transfected with the model peptide p33 derived from LCMV which was used as a positive control. The activated TILs were then co-cultured with BMDCs pulsed separately with the selected peptides. P33 peptide was used as a positive internal control while actin peptide was used as a negative control due to expected strong immune tolerance. IFN- γ production was then assessed by performing intra-cellular

cytokine staining (**Figures 4A,B**). The results indicated that the selected peptides were effective at inducing significant IFN- γ production by T-cells when compared to actin. There was no significant difference between p33 and the selected germline or mutated peptides.

Multi-Target VLP-Based Vaccine Using Cu-Free Click Chemistry Could Significantly Hinder the Progression of the Aggressive Transplanted B16F10 Tumor

Displaying peptides on CpG-loaded VLPs represents a unique possibility to increase their immunogenicity for T-cells. Hence, Q β -VLPs were used as a scaffold and packaged with B-type CpGs. The packaging was confirmed by agarose gel and the selected peptides were coupled to Q β -VLPs using Cu-free click chemistry. The vaccines were produced with germline epitopes (GL-MTV) identified by immunopeptidomics, mutated epitopes (Mutated-MTV) predicted by whole exome sequencing or a combination of both (Mix-MTV). The aim of preparing these groups separately was to compare their overall immunogenicity. The developed

vaccines were tested in WT C57BL/6 mice bearing the aggressive B16F10 melanoma tumors. We have adapted a challenging therapeutic murine melanoma model by transplanting $\sim 2\text{ mm}^3$ sized B16F10 tumor fragment into the flank of WT C57BL/6 mice and let it grow for 5 more days *in vivo* before vaccination started “**Figure 5A**.” In order to enhance the efficacy of the developed MTVs, they were combined with anti-CD25 mAb to deplete Tregs and facilitate CTLs infiltration. Anti-CD25 was chosen based on a number of preliminary data showing that anti PD-1 did not enhance the efficacy or immunogenicity of the developed multi-target VLP-based vaccines against B16F10 melanoma cell line, while anti-CD25 did (please note that Dacilizumab, the anti-CD25 antibody used in humans, does not deplete Tregs *in vivo*). The transplanted WT C57BL/6 mice were vaccinated s.c. with the developed MTV in combination with low dose of anti-CD25, 3 times over 14 days as the control groups reached the ethical end point by day 14 (**Figure 5B**). The depletion of Tregs characterized by CD4 $^{+}$, CD25 hi was assessed in the periphery of vaccinated mice on day 6 post tumor transplantation (**Figures 5C,D**). All three multi-target VLP-based vaccines could significantly hinder the progression of B16F10 melanoma tumor when assessing the tumor volume at day 14 in comparison to the groups vaccinated with Q β (CpGs)-VLP or anti-CD25 alone. However, anti-tumor protection was more efficient when vaccinating with Mix-MTV than with GL-MTV or Mutated-MTV (**Figures 5E,F**). Furthermore, when assessing the growth curve of the aggressive B16F10 tumors over the 14 days, only Mix-MTV showed significant reduction in the tumor growth ($p = 0.03$). Treatment with anti- Q β (CpGs)-VLP or CD25 mAb alone did not show any anti-tumor protection (**Figures 5G,H**).

TABLE 3 | The selected peptides from whole-exome sequencing for the generation of mutated-MTV.

Peptide	Sequence	# of a.a.	MHC haplotype	MHC-I affinity
Cpsf3l	TFADNPGPM	9	H2D ^b	0.8855
Kif18b	FQEFVDWENV	10	H2D ^b	1.7




FIGURE 4 | Validation of germline and mutated epitopes identified by immunopeptidomics and predicted by whole exome sequencing. (A) Percentage of CD8 $^{+}$ IFN- γ^{+} secreting cells (means \pm SEM) in duplicate, pre-gated on TILs. p33 peptide was used as a positive control and actin as a negative control. Statistical analysis by Student's *t*-test in comparison with Actin (–ve control). (B) Representative FACS plots showing the percentage of CD8 $^{+}$ IFN- γ^{+} secreting cells pre-gated on TILs and stimulated with Actin (–ve control), p33 (+ve control), ZFP518, Cpsf3l, PMEL17, and Kif18b peptides. One representative of 3 similar experiments is shown. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$.





FIGURE 5 | Multi-target VLP-based vaccine using Cu-free click chemistry could significantly hinder the progression of the aggressive transplanted B16F10 tumor. **(A)** A sketch of the challenging therapeutic murine melanoma model based on injecting $\sim 1 \times 10^6$ B16F10 melanoma cell line into the flank of C57BL/6 RAG2^{-/-} mice. Twelve to thirteen days later the growing tumors are collected and processed for transplantation of ~ 2 mm³ into the flank of C57BL/6 WT mice. **(B)** Vaccination scheme of five groups: Qβ(CpGs)-VLPs, anti-CD25, germline-multi target vaccine (GL-MTV), Mutated-MTV, and Mix-MTV GL-MTV. **(C)** Representative percentage of CD4⁺ CD25^{Hi} in the periphery of the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, and Mix-MTV+anti-CD25 on day 6 post-tumor transplantation. **(D)** Representative FACS plots showing the percentage of CD4⁺ CD25^{Hi} in periphery of the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, and Mix-MTV+anti-CD25 on day 6 post-tumor transplantation. **(E)** Photographic images of s.c. B16F10 tumors on day 14 post-tumor transplantation. **(F)** Tumor volume mm³ (means ± SEM) measured on day 14 post-tumor transplantation for the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV and Mix-MTV, each dot represents a tumor. Statistical analysis by Student's *t*-test. **(G)** Individual tumor growth curves of s.c. B16F10 melanoma of the designated groups. **(H)** Combined tumor growth curves of the designated groups, arrows indicate start of treatment. Statistical analysis by AUC. The groups of GL-MTV, Mutated-MTV, and Mix-MTV were combined with anti-CD25mAb in all experiments. (n = 5) mice per group, one representative of 3 similar experiments is shown. **P* < 0.05; ***P* < 0.01; ****P* < 0.001; *****P* < 0.0001.

Mix Multi-Target VLP-Based Vaccine Increased CD8⁺ T-Cell Infiltration Into B16F10 Tumor and Enhanced the Survival

It is readily accepted that high-grade CD8⁺ T-cell density in tumors is correlated with better prognosis and is an essential piece of evidence for effective immune responses (7, 30). Based on that, we measured the total number of infiltrating CD8⁺ T-cells in the tumors and calculated their density in each vaccinated group (by dividing the total number of CD8⁺ T-cells in each tumor by its volume). Mix-MTV significantly increased CD8⁺ T-cells density when compared to the groups vaccinated with Qβ(CpGs)-VLPs (*p* = 0.0028), anti-CD25 (*p* = 0.0076), or Mutated-MTV (*p* = 0.01). The statistical difference between Mix-MTV and GL-MTV was borderline significant (*p* = 0.06) (Figures 6A,C). When assessing the density of CD8⁺ IFN-γ⁺ secreting cells in the tumors, the data showed that Mix-MTV group induced the strongest cytokine production

which was superior to the groups vaccinated with GL-MTV or Mutated-MTV (Figure 6B). These results underline the effectiveness of combining both germline and mutated epitopes in one vaccine when treating the aggressively growing B16F10 melanoma tumor.

Whether the different multi-target VLP-based vaccines can extend the life-span of tumor-bearing mice was tested next. Tumors in control mice or mice treated with anti-CD25 mAb alone reached their ethically allowed maximal size of $\sim 1,000$ mm³ within 13–16 days, underscoring the aggressiveness of the model used. Vaccination with the GL-MTV or Mutated-MTV in combination with anti-CD25 mAb extended the mouse life-span by about 8 days while the Mix-MTV did so by about 16 days (Figure 6D). In fact, vaccination with the Mix-MTV reached protective levels of the vaccine based on p33 peptide, one of the strongest T-cell epitopes known in mice.



Mix Multi-Target Vaccine Altered the Myeloid Composition of B16F10 Tumor

We have studied next the effect of the vaccination with the prepared multi-target vaccines on tumor myeloid immune cell composition. Specifically, we have looked at both granulocytic and monocytic myeloid populations in TILs. There was an overall increase in the Ly6G⁺ granulocytic population in the groups vaccinated with Mix-MTV and GL-MTV in comparison to the control groups Q β (CpGs)-VLPs or anti-CD25. However, the infiltration of Ly6G⁺ granulocytes into the tumour was significantly higher in the group vaccinated with Mix-MTV when compared to the groups vaccinated with GL-MTV ($p = 0.0331$) or Mutated-MTV ($p = 0.0015$) (Figures 7A,C). The increase in the granulocyte population was accompanied by a decrease in monocytic population characterized by Ly6C⁺ which is shown prominently in the group vaccinated with Mix-MTV (Figures 7B,C). The observed increase in granulocytic population and the decrease in monocytic one was inversely correlated with the tumor volume ($p = 0.0003$) as shown in

(Figure 7D) and is compatible with induction of a more protective environment (31, 32).

DISCUSSION

VLPs have shown to be a promising platform for the development of effective vaccines. Such platforms significantly enhance the immunogenicity of tumor epitopes and help overcoming tolerance and anti-inflammatory milieu (33, 34). Indeed, it has been shown previously that a VLP-based vaccine can be utilized for active immunization against melanoma and vaccination against a single epitope resulted in strong CTL responses and exerted therapeutic pressure to the extent of provoking outgrowth of antigen escape variants in mice and humans (17, 18, 35). Personalized cancer vaccines targeting the patient's tumor specific mutanome may have the potential to generate clinically effective T-cell responses (14, 15). In previous studies, multi-target long peptides, or RNA-based vaccine have been used to induce CD8⁺ (and CD4⁺) T-cell responses in melanoma




FIGURE 7 | Mix multi-target vaccine altered the myeloid composition of B16F10 tumor. **(A)** Percentage of Ly6G⁺ cells (means \pm SEM) in TILs, pre-gated on CD45⁺ cells in the groups vaccinated with Qβ(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV, and Mix-MTV. **(B)** Percentage of Ly6C⁺ cells (means \pm SEM) in TILs, pre-gated on CD45⁺ cells in the vaccinated groups. Statistical analysis by one-way ANOVA. **(C)** Representative FACS plots showing the percentage of Ly6G⁺ and Ly6C⁺ cells in TILs in the vaccinated groups. **(D)** Correlation between the ratio of the percentage of Ly6G⁺ and Ly6C⁺ cells over the tumor volume mm³ in the vaccinated groups. Statistical analysis by linear regression. The groups of GL-MTV, Mutated-MTV, and Mix-MTV were combined with anti-CD25mAb in all experiments. (*n* = 5) mice per group, one representative of 3 similar experiments is shown. **P* < 0.05; ***P* < 0.01; ****P* < 0.001; *****P* < 0.0001.

patients. Interestingly, even though the vaccines were designed to induce CTL responses, they preferentially stimulated CD4⁺ T-cells, reminiscent of the generally acknowledged difficulties in mobilizing strong and broad CD8⁺ T-cell responses by vaccination (14, 15, 36, 37). Nevertheless, these findings support the concept that a multi-target vaccine covering a broader range of cancer antigens can control tumor progression and avoid outgrowth of antigen-escape variants.

In this study, a novel platform for the generation of a personalized VLP-based vaccine has been developed by combining both immunopeptidomics and whole exome sequencing techniques. Earlier versions of VLP-based vaccines using SMPH chemistry to couple antigens of interest to VLPs showed good efficacy. SMPH reacts with free Lysine on the VLP and free cysteine on the peptides. However, not only cysteines of the linker but also cysteines within the target epitope may react with SMPH, resulting in the inactivation of cysteine-containing epitopes. In addition, non-reacted SMPH on VLPs may be

toxic as it can react with cysteines in the body after injection of the vaccine. To overcome this problem and enable mixing and coupling of peptides with VLPs at bedside, a new coupling chemistry should be employed that leaves cysteines untouched and that will not react with anything in the host. To this end, bio-orthogonal Cu-free click chemistry has been implemented here for GMP-compatible production at bedside. The results show that DBCO is superior to SMPH cross-linker in terms of (1) coupling efficiency to Qβ-VLPs and (2) in inducing CTL and IFN-γ response *in-vivo*. Bio-orthogonal in general, refers to any chemical reaction that can occur in the living organism without causing cellular toxicity or interfering with natural biological reactions (38). Furthermore, the azide groups attached to the peptides are metabolically stable and lack any reactivity with natural biological functionalities in the cells as it only reacts with the alkyne groups (39, 40). This new coupling method has shown high selectivity for *in vivo* studies (41) such as for labeling, imaging, and tracking cells (39, 42). Cu-free click chemistry

has been recently applied for the synthesis of glucoconjugate O-antigen vaccine coupled to CRM₁₉₇ carrier protein against *Salmonella Typhimurium* (43).

Identification of optimal cancer-specific antigens remains a priority in the field of cancer immunotherapy. Some scientists favor peptides that are actually presented on the tumor cells using immunopeptidomics and others rely on epitope prediction based on whole exome sequencing. The promising clinical trials conducted so far to test a personalized cancer vaccine have mainly used whole exome sequencing validated by RNA-seq to predict tumor-specific neoantigens. Immunopeptidomics identifies peptides that are actually presented but requires relatively large amounts of tumor-tissue. By comparison, whole exome sequencing can be performed with minimal cell numbers, but epitopes are only predicted and their presence is not actually physically assessed. In addition, the relative merits of germline vs. mutated epitopes for vaccine design is also disputed. While the former may be conserved in many patients, the latter likely induce less or even no immune tolerance, as they are not expressed in the thymus during early development nor in the periphery other than in tumor cells (14, 15, 44). In our study, to directly compare the different approaches, both immunopeptidomics and whole exome sequencing were performed to identify and predict both types of T-cell epitopes. Several T-cell epitopes have been identified and prioritized by bioinformatics, as well as by their ability to stimulate TILs from tumor-bearing mice. TILs are highly enriched with specific T-cells and thus the most relevant T-cell population for anti-tumor T-cell responses. Using these approaches, two sets of peptides, germline and mutated epitopes, were identified and displayed on VLPs loaded with CpGs. In recent years, it has become evident that anti-tumor response may be enhanced in the presence of checkpoint inhibitors. Blocking PD-1 vs. depleting Tregs using anti-CD25 mAb was compared. While blocking PD-1 had minimal impact on B16F10 tumor growth, anti-CD25 mAb substantially enhanced protection. Therefore, the developed multi-target VLP-based vaccines were combined with anti-CD25 mAb treatment. The results showed that using germline peptides or mutated or a mixture of both can confer protection against tumor growth in B16F10 melanoma model. Interestingly, mixing both types of epitopes was most promising. This effect was also shown when calculating the density of CD8⁺ T-cells or CD8⁺ IFN- γ ⁺ secreting cells in TILs and when assessing the effect of the vaccines on the myeloid composition of the tumor. Indeed, protection using the Mix-MTV was as potent as observed with the artificial model antigen, peptide p33, one of the strongest T-cell epitopes known in mice.

It has been shown previously that eliminating large established tumors is challenging even in pre-clinical studies. Kelly et al. has shown that curing a B16F10 melanoma tumor sized 60–80 mm² is possible when combining four immunotherapeutic agents (31). Here, we have used a more challenging model employing transplanted solid tumors rather than single cell suspension, resulting in tumors with physiological stroma and vascularization. Combining the multi-target VLP-based vaccine with anti-CD25 doubled the lifespan

of the transplanted mice and changed the immunological milieu of the tumors, which is an impressive result given the model used.

The approach of vaccinating with only two neoantigens and combining them with germ-line antigens avoids the need for identifying large numbers of neoantigens that may represent a particular problem in tumors of low mutational burden. A prominent example of this is the aggressive metastatic breast cancer murine cell line 4T1. It has been shown that 4T1 harbored 27 mutations in their expressed genes, however only one mutation was predicted to bind MHC-I H2-D^b allele (45). These data are consistent with the fact that human tumors associated with environmental mutagens such as melanoma have more mutations than other cancers (46). Additionally, Keeping the numbers of neoantigens low may also simplify the production of this type of personalized vaccines to some extent, as the final vaccine formulations would vary less from one patient to the next one, easing the regulatory challenges for producing and releasing these pharmaceutical products for clinical use.

In conclusion, this study proposes a novel platform for the development of an immunogenic personalized melanoma vaccine based on VLPs. This vaccine utilizes CTL epitopes predicted and validated by both immunopeptidomics and whole exome sequencing techniques. The peptides were coupled to the highly immunogenic VLPs by Cu-free click chemistry, representing a fast, safe and efficient method of coupling, enabling GMP compliant production for future use in clinical settings. The platform developed here can be used to target potentially any malignant tumor and thus can be applied broadly in cancer medicine.

ETHICS STATEMENT

Animal procedures were conducted at the University of Bern, Switzerland, in accordance with the Swiss Animals Act (455.109.1, September 2008, 5th, University of Bern).

AUTHOR CONTRIBUTIONS

MM, MV, CR, DS, and MB: design of experiments, acquisition of data, interpretation of data, analysis of data. NT and JM: immunopeptidomics acquisition and data analysis. JM and SS: exome sequencing data analysis. MM, MV, AE-T, GC-M, AG, CR, TK, AK, DS, SD, and MB: writing, revise and revision of manuscript. MM, MV, and CR: technical and material support. MB: study supervision.

FUNDING

This work was supported by the Swiss Cancer League (KFS-4132-02-2017) and Qatar National Research Fund (PDRA grant PDRA4-0118-18002).

ACKNOWLEDGMENTS

The publication of this article was funded by the Qatar National Library.

REFERENCES

- Luo C, Shen J. Research progress in advanced melanoma. *Cancer Lett.* (2017) 397:120–6. doi: 10.1016/j.canlet.2017.03.037
- Vasquez M, Tenesaca S, Berraondo P. New trends in antitumor vaccines in melanoma. *Ann Transl Med.* (2017) 5:384. doi: 10.21037/atm.2017.09.09
- Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. *Nat Rev Immunol.* (2018) 18:168–82. doi: 10.1038/nri.2017.131
- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell.* (2006) 124:783–801. doi: 10.1016/j.cell.2006.02.015
- Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. *Curr Gene Ther.* (2011) 11:307–20. doi: 10.2174/156652311796150372
- Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. *Cancer Immunol Res.* (2013) 1:11–5. doi: 10.1158/2326-6066.CIR-13-0022
- Lee N, Zakka LR, Mihm MC, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. *Pathology.* (2016) 48:177–87. doi: 10.1016/j.pathol.2015.12.006
- Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. *Cancer Res.* (2012) 72:1081–91. doi: 10.1158/0008-5472.CAN-11-3722
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity.* (2013) 39:1–10. doi: 10.1016/j.immuni.2013.07.012
- Kruit WH, Suci S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma. *J Clin Oncol.* (2013) 31:2413–20. doi: 10.1200/JCO.2012.43.7111
- Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Stratton MR. Signatures of mutational processes in human cancer. *Nature.* (2013) 500:415–21. doi: 10.1038/nature12477
- Strasner A, Karin M. Immune infiltration and prostate cancer. *Front Oncol.* (2015) 5:128. doi: 10.3389/fonc.2015.00128
- Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: from mechanisms to therapy. *Cancers.* (2018) 10:6. doi: 10.3390/cancers10010006
- Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature.* (2017) 547:217–21. doi: 10.1038/nature22991
- Sahin U, Derhovanessian E, Miller M, Kloeke BP, Simon P, Tureci O. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. *Nature.* (2017) 547:222–6. doi: 10.1038/nature23003
- Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. *Science.* (2015) 348:803–8. doi: 10.1126/science.aaa3828
- Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devedre E, Sterry W, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. *J Immunother.* (2010) 33:848–58. doi: 10.1097/CJI.0b013e3181fd614
- Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, et al. Nano-particle vaccination combined with TLR-7 and-9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. *Eur J Immunol.* (2012) 42:3049–61. doi: 10.1002/eji.201142361
- Kozlovskaya TM, Cielens I, Vasiljeva I, Strelnikova A, Kazaks A, Dislers A, et al. RNA phage Q beta coat protein as a carrier for foreign epitopes. *Intervirology.* (1996) 39:9–15. doi: 10.1159/000150469
- Cielens I, Ose V, Petrovskis I, Strelnikova A, Renhofa R, Kozlovskaya T, et al. Mutilation of RNA phage Qbeta virus-like particles: from icosahedrons to rods. *FEBS Lett.* (2000) 482:261–4. doi: 10.1016/S0014-5793(00)02061-5
- Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, Dumrese T, et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. *J Immunol.* (2002) 168:2880–6. doi: 10.4049/jimmunol.168.6.2880
- Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *Quant Biol Genom.* arXiv:1303.3997 [q-bio.GN] (2013).
- Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. Genome project data processing. The sequence alignment/Map format and SAMtools. *Bioinformatics.* (2009) 25 2078–9. doi: 10.1093/bioinformatics/btp352
- Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SR F, Lunter G. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. *Nat Genet.* (2014) 46:912–8. doi: 10.1038/ng.3036
- McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Cunningham F. The ensembl variant effect predictor. *Genome Biol.* (2016) 17:122. doi: 10.1186/s13059-016-0974-4
- Storni T, Bachmann MF. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative *in vivo* comparison. *J Immunol.* (2004) 172:6129–35. doi: 10.4049/jimmunol.172.10.6129
- Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi A, et al. Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines. *Front Immunol.* (2017) 8:226. doi: 10.3389/fimmu.2017.00226
- Mohsen MO, Gomes AC, Cabral-Miranda G, Krueger CC, Leoratti FM. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. *J Control Release.* (2017) 251:92–100. doi: 10.1016/j.jconrel.2017.02.031
- Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. *Br J Cancer.* (2011) 105:93–103. doi: 10.1038/bjc.2011.189
- Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl T, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. *Cancer Immunol Immunother.* (2006) 55:451–8. doi: 10.1007/s00262-005-0018-5
- Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Irvine DJ. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. *Nat Med.* (2016) 22:1402–10. doi: 10.1038/nm.4200
- Murray AA, Wang C, Fiering S, Steinmetz NF. *In situ* vaccination with cowpea vs tobacco mosaic virus against melanoma. *Mol Pharm.* (2018) 15:3700–16. doi: 10.1021/acs.molpharmaceut.8b00316
- Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat Rev Immunol.* (2010) 10:787–96. doi: 10.1038/nri2868
- Makkouk A, Weiner G J. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. *Cancer Res.* (2015) 75:5–10. doi: 10.1158/0008-5472.CAN-14-2538
- Schwarz K, Meijerink E, Speiser DE, Tissot AC, Cielens I, Bachmann MF. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. *Eur J Immunol.* (2005) 35:816–21. doi: 10.1002/eji.200425755
- Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. *Oncoimmunology.* (2013) 2:e27010. doi: 10.4161/onci.27010
- Donaldson B, Al-Barwani F, Pelham SJ, Young K, Ward VK, Young SL. Multi-target chimeric VLP as a therapeutic vaccine in a model of colorectal cancer. *J Immunother Cancer.* (2017) 5:69. doi: 10.1186/s40425-017-0270-1
- Chang PV, Prescher JA, Sletten EM, Baskin JM, Miller IA, Bertozzi CR. Copper-free click chemistry in living animals. *Proc Natl Acad Sci USA.* (2010) 107:1821–6. doi: 10.1073/pnas.0911116107
- Baskin JM, Prescher JA, Laughlin ST, Agard NJ, Chang PV, Bertozzi CR. Copper-free click chemistry for dynamic *in vivo* imaging. *Proc Natl Acad Sci USA.* (2007) 104:16793–97. doi: 10.1073/pnas.0707090104
- Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF. Major findings and recent advances in virus-like particle (VLP)-based vaccines. *Semin Immunol.* (2017) 34:123–32. doi: 10.1016/j.smim.2017.08.014

41. Jewett JC, Bertozzi CR. Cu-free click cycloaddition reactions in chemical biology. *Chem Soc Rev.* (2010) 39:1272–9. doi: 10.1039/b901970g
42. Yoon HI, Yhee JY, Na JH, Lee S, Lee H, Kim K, et al. Bioorthogonal copper free click chemistry for labeling and tracking of chondrocytes *in vivo*. *Bioconjug Chem.* (2016) 27:927–36. doi: 10.1021/acs.bioconjchem.6b00010
43. Stefanetti G, Saul A, MacLennan CA, Micoli F. Click chemistry applied to the synthesis of salmonella typhimurium o-antigen glycoconjugate vaccine on solid phase with sugar recycling. *Bioconjug Chem.* (2015) 26:2507–13. doi: 10.1021/acs.bioconjchem.5b00521
44. Kroemer G, Zitvogel L. Can the exome and the immunome converge on the design of efficient cancer vaccines? *Oncoimmunology.* (2012) 1:579–80. doi: 10.4161/onci.20730
45. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. *Proc Natl Acad Sci USA.* (2014) 111:11774–9. doi: 10.1073/pnas.1410626111
46. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAW. Cancer genome landscapes. *Science.* (2013) 339:1546–58. doi: 10.1126/science.1235122

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Mohsen, Vogel, Riether, Muller, Salatino, Ternette, Gomes, Cabral-Miranda, El-Turabi, Ruedl, Kundig, Dermime, Knuth, Speiser and Bachmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.